Corbus Pharmaceuticals Holdings, Inc. has announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701 (SYS6002), which targets Nectin-4 in patients with ...

In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $75.00. The company’s ...

Corbus Pharmaceuticals has a 52 week low of $9.11 and a 52 week high of $61.90. The stock has a market cap of $119.11 million, a P/E ratio of -2.09 and a beta of 2.63. Institutional Inflows and ...

Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe of CRB-701 has been released. The ...

The J.P. Morgan Healthcare Conference is invitation only. Those interested in attending should contact their J.P. Morgan representative for more information. This press release contains certain ...